MarketBucinnazine
Company Profile

Bucinnazine

Bucinnazine is an opioid analgesic drug that was widely used in China to treat pain in cancer patients as of 1986. It is one of the most potent compounds among a series of piperazine-amides first synthesized and reported in Japan in the 1970s. Bucinnazine has analgesic potency comparable to that of morphine, but with a relatively higher therapeutic index.

Derivatives
2-Methyl-AP-237 has been sold on the grey market as a designer opioid, first identified by a police forensic laboratory in Slovenia in March 2019. In 2023, the United States Department of Justice took criminal action against two individuals for selling 2-Methyl-AP-237 under the false pretenses that such product was intended for 'research purposes' only. One of the pair was sentenced to five years in federal prison. The WHO and the Ministry of Social Affairs, Health, Care and Consumer Protection have published reports on 2-Methyl-AP-237. According to their analysis, it is a little bit less potent than fentanyl and can be reversed using naltrexone. There haven't been any studies on its systemic toxicity but there have been overdose deaths linked to it, most in combination with other drugs. It is primarily consumed orally or through snorting. While the methyl substitution creates a stereocenter, the drug is sold as the racemat. ] ==See also==
tickerdossier.comtickerdossier.substack.com